Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
20.87
+0.38 (1.85%)
At close: Oct 2, 2025, 4:00 PM EDT
20.81
-0.06 (-0.29%)
After-hours: Oct 2, 2025, 6:34 PM EDT
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
159
Market Cap
15.50B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
Dec 31, 2020 | 860.00K | 49.46K | 6.10% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jan 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jan 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jan 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SMMT News
- 8 days ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 8 days ago - HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 - Business Wire
- 10 days ago - Ten Bull Market 10-Baggers - Seeking Alpha
- 14 days ago - Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential - FXEmpire
- 16 days ago - Summit Therapeutics Inc. Investigated by the Portnoy Law Firm - GlobeNewsWire
- 22 days ago - CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm - GlobeNewsWire
- 23 days ago - Top 3 Health Care Stocks You'll Regret Missing In Q3 - Benzinga
- 24 days ago - Summit Therapeutics (SMMT) WCLC Update Call (Transcript) - Seeking Alpha